KevinMarkShannonMD

PubMed

• 24 citations
  MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
  Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave,...> ;Neuro-Oncology. 2022 Nov 2
• 8 citations
  High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions
  Marsilius Mues, Laila Karra, Damia Romero-Moya, Anica M. Wandler, Matthew J. Hangauer, Olga Ksionda, Yvonne Thus, Marthe F. Lindenbergh, Kevin Shannon, Michael T. McMa...> ;Cell Reports. 2019 Apr 9
• 5 citations
  Subvalvular catheter ablation of the cavotricuspid isthmus in a patient with Ebstein's anomaly and tricuspid valve replacement.
  Gallotti, R. G., Shannon, K. M., Moore, J. P.> ;HeartRhythm case reports.
• 69 citations
  The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
  Nina Fenouille, Christopher F. Bassil, Issam Ben-Sahra, Lina Benajiba, Gabriela Alexe, Azucena Ramos, Yana Pikman, Amy Saur Conway, Michael R. Burgess, Qing Li, Freder...> ;Nature Medicine. 2017 Mar 1
• 48 citations
  Predictors of myocardial recovery in pediatric tachycardia-induced cardiomyopathy.
  Moore, J. P., Patel, P. A., Shannon, K. M., Albers, E. L., Salerno, J. C., Stein, M. A., Stephenson, E. A., Mohan, S., Shah, M. J., Asakai, H., Pflaumer, A., Czosek, R...> ;Heart rhythm.
• Join now to see all